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Objective: There is evidence for an association between levels of urinary C-telopeptide fragments of type
II collagen (uCTX-II) and risk of knee osteoarthritis (OA). The aim of this cohort study was to examine the
association between uCTX-II levels and knee cartilage and bone changes in middle-aged women without
clinical knee disease.
Design: 140 women, aged 40e67 years, with no signiﬁcant knee pain, knee injury or any forms of
arthritis, underwent knee magnetic resonance imaging (MRI) at baseline and 2 years later. Cartilage
volume, cartilage defects, tibial plateau bone area and bone marrow lesions (BMLs) were measured using
validated methods. Baseline uCTX-II was measured using enzyme-linked immunosorbent assay (ELISA).
Results: For every one unit (natural logarithm transformed) increase in baseline uCTX-II level, there was
an increase in the prevalence of medial tibiofemoral cartilage defects (Odds ratio (OR) 4.36, 95%
conﬁdence interval (CI) 1.58e12.04), medial (80.2 mm2, 95% CI 9.3e151.1) and lateral (86.0 mm2, 95% CI
33.3e138.7) tibial plateau bone area, and the prevalence of lateral tibiofemoral BMLs (OR 10.62, 95% CI
1.82e61.85). Baseline uCTX-II levels were not signiﬁcantly associated with baseline tibial cartilage vol-
ume or changes in knee cartilage volume or defects or bone area over 2 years, although there was a trend
for the deterioration of medial tibiofemoral BMLs (P ¼ 0.06).
Conclusion: In middle-aged women without clinical knee disease, higher uCTX-II levels were associated
with early detrimental structural changes at the knee (cartilage defects, tibial bone expansion and BMLs)
at baseline but not over 2 years. Further work will be needed to determine its sensitivity to change and
whether it predicts disease progression over longer time periods.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Knee osteoarthritis (OA) is a disease of the whole joint, affecting
both articular cartilage and subchondral bone. There are no current
treatments that have been shown to slow disease progressiono: Y. Wang, Department of
versity, Alfred Hospital, Mel-
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ternational. Published by Elsevier Lexcept for signiﬁcant weight loss1 which is difﬁcult to achieve. Thus
prevention is critical to reduce the burden of the disease. Many
studies have focused on the early detection of knee OA by assessing
cartilage volume, cartilage defects, tibial plateau bone area, and
bone marrow lesions (BMLs) using magnetic resonance imaging
(MRI)2,3.
Despite the new imaging modalities, serum or urinary bio-
markers may represent another sensitive method of the assess-
ment of early knee cartilage and bone changes. There is emerging
data suggesting an association between the levels of urinary C-
telopeptide fragments of type II collagen (uCTX-II) and risk of knee
OA. uCTX-II levels have been associated with the presence and
severity of knee OA4e6, progression of radiographic knee OA5,7,8,
and predict longitudinal cartilage loss9,10. Only one study found notd. All rights reserved.
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progression over 30 months11. In a cohort study of 377 patients
with painful knee OA, baseline uCTX-II levels were associated with
the severity of BMLs and predicted BML worsening over 3 months,
and change in uCTX-II levels was associated with BML changes over
3 months12. uCTX-II has also been associated with cartilage defect
severity in a cross-sectional convenience sample of 372 partici-
pants13. However, there are little data on the association between
uCTX-II concentration and early structural features that precede
knee OA in populations without clinical knee OA, to determine
whether uCTX-II might be a sensitive biomarker of early structural
changes of knee OA and predict longitudinal structural changes at
the knee. Understanding this association may have clinical impli-
cations by using uCTX-II as a biomarker to identify people at higher
risk of developing knee OA who may be candidates for disease
prevention and early intervention.
The aim of this study was to examine the association between
uCTX-II levels and knee cartilage and bone changes in a cohort of
middle-aged women without clinical knee disease.
Method
Study participants
Study participants were recruited from a previous cross-
sectional study of 1423 women examining the role of androgens
in sexual function using a database established from the electoral
roll in Victoria, Australia14. Women were eligible for the current
prospective cohort study if they were aged 40e67 years, had not
undergone a hysterectomy and agreed to be re-contacted for
further studies. Of the 355 women who fulﬁlled these criteria, 176
remained eligible after further exclusion for signiﬁcant knee pain
lasting >24 h in the past 5 years that necessitated treatment by a
doctor or physiotherapist, knee injury in the last 5 years requiring
non-weight-bearing treatment for >24 h or surgery, any arthritis
diagnosed by a medical practitioner, any contraindication to MRI
scan including pacemaker, metal sutures, presence of shrapnel or
iron ﬁlings in the eye, or claustrophobia, or being unlikely to be
available to complete the longitudinal protocol of re-assessment at
2 years15. The women were largely asymptomatic, which was evi-
denced by the very low score of theWestern Ontario andMcMaster
Universities Arthritis Index (WOMAC) pain and stiffness subscales
at baseline, with the median scores being 22 out of 500 and 7 out of
200, respectively. The study was approved by the Southern Health
Human Research and Ethics Committee and the Monash University
Human Research and Ethics Committee. All participants gave
written informed consent.
Anthropometric measurements
Weight was measured to the nearest 0.1 kg using electronic
scales with shoes, socks, and bulky clothing removed. Height was
measured to the nearest 0.1 cm using a stadiometer with shoes and
socks removed. Body mass index (BMI) (weight/height2, kg/m2)
was then calculated from these measurements.
Measurement of uCTX-II
The urine was collected from the ﬁrst void urine sample within
2 h of waking on the day of knee MRI and stored at 80C until
analysis. uCTX-II concentration was measured using a commercial
enzyme-linked immunosorbent assay (ELISA) test (Urine Carti-
Laps®; Nordic Bioscience, Herlev, Denmark) and samples were
analyzed in duplicate in according to manufacturer's protocol
(intra-assay coefﬁcients of variation (CVs) was <8.7%). uCTX-IIlevels were normalized with urinary creatinine concentration
determined by creatinine (urinary) assay kit (Cayman Chemical
Company, Ann Arbor, Michigan 48108, USA) according to manu-
facturer's protocol.
Knee MRI and knee structure measurement
An MRI of each participant's dominant knee, deﬁned as the leg
from which the participant stepped off from when initiating gait,
was performed during 2003e200415 and approximately 2 years
later. Knees were imaged in the sagittal plane on a 1.5-T whole body
magnetic resonance unit (Philips Medical Systems, The
Netherlands) using a commercial transmit-receive extremity coil.
The following sequence and parameters were used: a T1-weighted
fat suppressed 3D gradient recall acquisition in the steady state, ﬂip
angle 55, repetition time 58 ms, echo time 12 ms, ﬁeld of view
16 cm, 60 partitions, 512  512 matrix, one acquisition time 11 min
56 s. Sagittal images were obtained at a partition thickness of
1.5 mm and an in-plane resolution of 0.31 0.31 mm. In addition, a
coronal T2-weighted fat-saturated acquisition, repetition time
2200 ms, echo time 20/80 ms, slice thickness 3.0 mm, 1.0 mm
interslice gap, one excitation, ﬁeld of view 11e12 cm and matrix of
256  128 pixels was obtained. All MRI images were analyzed
unpaired, by one trained observer with random cross-checks per-
formed by a second trained observer, both blinded to participants'
characteristics and sequence of MRIs.
Cartilage volume measurement
The volumes of the individual cartilage plates (medial and
lateral tibial) were measured from the total volume by manually
drawing disarticulation contours around the cartilage boundaries
on each section on a workstation using the Osiris software (Uni-
versity Hospital of Geneva). The CVs for the medial and lateral
cartilage volume measures were 3.4% and 2.0% respectively16.
Annual change in cartilage volume was calculated as (follow-up
cartilage volume subtracted from baseline cartilage volume)
divided by the period of time between MRI scans16. Annual per-
centage change was obtained by dividing annual change by base-
line cartilage volume, expressed as a percentage.
Assessment of cartilage defects
Cartilage defects were graded on the MR images with a classi-
ﬁcation system in the medial and lateral tibial and femoral carti-
lages. The grading was as follows: grade 0, normal cartilage; grade
1, focal blistering and intracartilaginous low-signal intensity area
with an intact surface and bottom; grade 2, irregularities on the
surface or bottom and loss of thickness of less than 50%; grade 3,
deep ulceration with loss of thickness of more than 50%; grade 4,
full-thickness cartilage wear with exposure of subchondral bone.
The intra- and inter-observer reliability (expressed as intraclass
correlation coefﬁcient (ICC)) was 0.90 and 0.90 for the medial and
0.89 and 0.85 for the lateral tibiofemoral compartment, respec-
tively13. A cartilage defect was identiﬁed as present if grade 2 at
either femoral or tibial cartilage within the medial or lateral
tibiofemoral compartment. Deterioration of cartilage defects was
deﬁned if follow-up cartilage defect grade was greater than base-
line grade in either tibial or femoral cartilage in themedial or lateral
compartment.
Bone area measurement
Medial and lateral cross-sectional areas of tibial plateau were
measured from reformatted axial images. The ﬁrst image which
showed both tibial cartilage and subchondral bone was identiﬁed.
The areas of medial and lateral tibial plateau bones were measured
on this image and the next distal imagemanually. An average of the
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Osteophytes, if present, were not included in the tibial bone area
measurement. CVs for the medial and lateral tibial plateau areas
were 2.3% and 2.4%, respectively17. Annual change in bone area was
calculated as (baseline bone area subtracted from follow-up bone
area) divided by the period of time between MRI scans17. Annual
percentage change was obtained by dividing annual change by
baseline bone area, expressed as a percentage.
Assessment of BMLs
BMLs were deﬁned as areas of increased signal intensity within
subchondral bone in either the distal femur or the proximal tibia
assessed from coronal T2-weighted images18. The grading was as
follows: grade 0, no BMLs; grade 1, deﬁnite BMLs, appeared on 2
adjacent slices and encompassed at least one quarter of the width
of medial or lateral compartment; grade 2, large BMLs, appeared on
3 slices18. The reproducibility for determination of BMLs was
assessed using 60 randomly selected knee MRIs (к value 0.88,
P < 0.001). Deterioration of BMLs was deﬁned if follow-up BML
grade was greater than baseline grade in either tibial or femoral
cartilage in the medial or lateral compartment.
Statistical analysis
uCTX-II levels determined by ELISA assays were not normally
distributed, thus a natural logarithm (Ln) transformation of uCTX-II
levels was performed. The outcome measures were cartilage vol-
ume, cartilage defects, tibial plateau bone area, and BMLs, in both
cross-sectional and longitudinal analyses. Cartilage volume, tibial
plateau bone area, and their changes over 2 years were continuous
variables with normal distribution, thus multiple linear regression
models were used to examine the associations. The prevalence and
deterioration of cartilage defects and BMLs were dichotomous
variables, thus binary logistic regression models were used to
examine the associations. All analyses were adjusted for potential
confounders including age, BMI, and tibial bone area for cartilage
outcomes. A P-value of <0.05 (two-tailed) was considered as sta-
tistically signiﬁcant. All analyses were performed using IBM SPSS
version 20.0.
Results
Of the 176 women, 36 women did not have baseline uCTX-II
measurement or follow-up knee MRI, thus 140 women were
included for statistical analyses (Table I). The mean follow-up time
was 2.2 (SD 0.1) years. There were no signiﬁcant differences in BMI
and knee structure measurements between those completed theTable I
Characteristics of study participants
Characteristics N ¼ 140
Age, years 52.9 (6.6)
BMI, kg/m2 27.2 (5.6)
Medial tibial cartilage volume, mm3 1492 (272)
Lateral tibial cartilage volume, mm3 1754 (339)
Medial tibial bone area, mm2 1968 (173)
Lateral tibial bone area, mm2 1236 (131)
Prevalence of medial tibiofemoral cartilage defects, n (%) 45 (32)
Prevalence of lateral tibiofemoral cartilage defects, n (%) 35 (25)
Prevalence of medial tibiofemoral BMLs, n (%) 9 (6)
Prevalence of lateral tibiofemoral BMLs, n (%) 11 (8)
uCTX-II, ng/mg Ucr 11.6 (9.0, 17.5)
Range 3.3e39.9
Ln uCTX-II 2.5 (0.5)
Data presented as mean (SD), n (%), or median (interquartile range) where
appropriate.study and thosewho did not, except that the completers were older
than the non-completers [52.9 (SD 6.6) vs 50.0 (SD 6.3) years,
P ¼ 0.03].
Association between uCTX-II and cartilage volume and prevalence of
cartilage defects
There was no signiﬁcant association between uCTX-II levels and
tibial cartilage volume in either univariate analysis or after adjusted
for age, BMI, and tibial bone area (Table II). Higher levels of uCTX-II
were associated with increased prevalence of medial and lateral
tibiofemoral cartilage defects in univariate analysis. After adjusted
for age, BMI, and tibial bone area, only the association for medial
tibiofemoral cartilage defects remained signiﬁcant [Odds ratio (OR)
4.36, 95% conﬁdence interval (CI) 1.58e12.04, P ¼ 0.004].
Association between uCTX-II and tibial bone area and prevalence of
BMLs
In both univariate analysis and after adjusting for age and BMI,
higher uCTX-II levels were associated with increased medial and
lateral tibial bone area (Table III). Adjustment for body height (to
take into account the body size) and weight instead of BMI did not
change the results (data not shown). Increased uCTX-II levels were
also associated with increased prevalence of BMLs in lateral tibio-
femoral compartment in both univariate analysis and after
adjusting for age and BMI (OR 10.62, 95% CI 1.82e61.85), but no
signiﬁcant association was observed for the prevalence of medial
tibiofemoral BMLs.
Association between uCTX-II and annual change in cartilage volume
and deterioration of cartilage defects over 2 years
Over 2 years, medial and lateral tibial cartilage volume reduced
by 2.8% (SD 3.1%) and 1.6% (SD 2.8%), respectively. The deterioration
of medial and lateral tibiofemoral cartilage defects was observed in
43 (30.7%) and 52 (37.1%) women, respectively. Baseline uCTX-II
levels did not predict annual change in tibial cartilage volume
and deterioration of tibiofemoral cartilage defects over 2 years, in
univariate analysis or adjusted for age, BMI, and tibial bone area
(Table IV).
Association between uCTX-II and annual change in tibial bone area
and deterioration of BMLs
Over 2 years, medial tibial bone area reduced by 0.2% (SD 1.9%),
while lateral tibial bone area increased by 1.3% (SD 3.6%). The
deterioration of medial and lateral tibiofemoral BMLs was observed
in 10 (7.1%) and 4 (2.9%) women, respectively. Baseline uCTX-II
levels did not predict annual change in tibial bone area over 2
years, in univariate analysis or adjusted for age and BMI. Higher
baseline uCTX-II levels were associated increased risk of deterio-
ration of medial tibiofemoral BMLs in univariate analysis (Table V).
The association was marginally signiﬁcant after adjusted for age
and BMI (OR 5.12, 95% CI 0.92e28.65, P ¼ 0.06). No signiﬁcant as-
sociation was observed for the deterioration of lateral tibiofemoral
BMLs.
Including use of the oral contraceptive pill and hormone
replacement therapy in the above regression models did not alter
the results (data not shown).
Discussion
Our study demonstrated that in middle-aged women without
clinical knee disease, higher uCTX-II levels were associated with
Table II
Association between uCTX-II and knee cartilage volume and prevalence of cartilage defects at baseline
Univariate analysis P value Multivariate analysisz P value
Regression coefﬁcient/OR (95% CI) Regression coefﬁcient/OR (95% CI)
Tibial cartilage volume (mm3)*
Medial tibial cartilage volume 2.7 (99.4, 94.1) 0.96 16.4 (121.5, 88.7) 0.76
Lateral tibial cartilage volume 76.8 (196.7, 43.0) 0.21 21.9 (117.1, 160.9) 0.76
Prevalence of cartilage defects (yes/no)y
Medial tibiofemoral cartilage defects 6.55 (2.67, 16.11) <0.001 4.36 (1.58, 12.04) 0.004
Lateral tibiofemoral cartilage defects 2.52 (1.08, 5.85) 0.03 1.15 (0.38, 3.48) 0.80
* Regression coefﬁcient.
y OR.
z Adjusted for age, BMI, and tibial bone area.
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increased prevalence of tibiofemoral cartilage defects and BMLs
and greater tibial plateau bone area. Although no signiﬁcant pre-
dictive effect of uCTX-II was found for knee structural changes over
2 years, higher baseline uCTX-II levels were associated with the
deterioration of BMLs over 2 years that approached statistical
signiﬁcance.
Previous studies have examined the association between uCTX-
II concentrations and knee cartilage properties assessed by MRI.
Consistent with the ﬁndings from a previous cross-sectional study
in a convenience sample of 372 participants13, we found a positive
association between uCTX-II levels and the prevalence of cartilage
defects. However we did not observe any association between
baseline uCTX-II levels and change in cartilage volume or cartilage
defects over 2 years. This is in keeping with the ﬁndings from a
cohort study that baseline uCTX-II levels were not correlated with
the 1 year change in cartilage volume and thickness in patients with
knee OA10. In contrast, another cohort study showed that higher
baseline uCTX-II levels were associated with greater cartilage vol-
ume loss over 21 months in 158 subjects with 23% having radio-
graphic knee OA9. Taken together, these data support a positive
association between uCTX-II levels and adverse cartilage
morphology, namely cartilage defects. There is increasing evidence
suggesting that cartilage defects are seen prior to the onset of
symptomatic knee OA and predate cartilage volume loss19,20. In
previous studies of participants without clinical knee OA, cartilage
defects have been shown to be a more sensitive measure of carti-
lage damage as cartilage loss tends to occur at a later stage in the
disease process21,22. We have detected adverse effects of higher
uCTX-II concentrations on cartilage defects but not cartilage vol-
ume. It is likely that our population consisted of community-based
womenwithout clinical knee disease and thus the rates of cartilage
change are lower than in a population where a signiﬁcant propor-
tion had knee OA9. This may have limited the power of our study to
detect the predictive effect of baseline uCTX-II on longitudinal
cartilage changes as we only followed these women over 2 years.Table III
Association between uCTX-II and tibial bone area and prevalence of BMLs at baseline
Univariate analysis
Regression coefﬁcient/OR (95% CI)
Tibial bone area (mm2)*
Medial tibial bone area 80.1 (19.8, 140.3)
Lateral tibial bone area 66.4 (21.2, 111.5)
Prevalence of BMLs (yes/no)y
Medial tibiofemoral BMLs 2.29 (0.54, 9.70)
Lateral tibiofemoral BMLs 5.98 (1.44, 24.89)
* Regression coefﬁcient.
y OR.
z Adjusted for age and BMI.However, our ﬁndings suggest that uCTX-II may be a sensitive
biomarker to detect early cartilage changes associated with the
development of knee OA, namely cartilage defects. We have
observed the association in the medial rather than the lateral
compartment, which is the compartment most susceptible to
loading and where OA is more common23,24.
Our study found uCTX-II was associated with adverse sub-
chondral bone changes, including increased prevalence of BMLs
and increased tibial plateau bone area. There are few data exam-
ining the association between CTX-II and subchondral bone
changes. CTX-II has traditionally been considered a biomarker of
solely cartilage degeneration. Recently there is emerging evidence
for its role in bonemetabolism. CTX-II is found close to subchondral
bone, including vascularization sites and bone-cartilage interface,
which is the prevailing position of CTX-II25. This may be relevant to
the possible role of subchondral bone in OA25. Another study re-
ported that uCTX-II had unique associations with bone markers as
compared with other cartilage markers and thus it might reﬂect
bone rather than cartilage metabolism26. In a recent study with the
deﬁnition of ﬁve clusters within a wide spectrum of biochemical
markers for OA, uCTX-II was clustered with bone metabolism bio-
markers27. Taken together these ﬁndings suggest that CTX-II may
not only reﬂect articular cartilage but also bone metabolism.
Furthermore, uCTX-II levels have shown association with the
severity and worsening of BMLs in patients with knee OA12. Our
study showed similar ﬁndings regarding uCTX-II and BMLs in a
population of healthy women without clinical knee disease.
Furthermore, our study is the ﬁrst study demonstrating an associ-
ation between increased uCTX-II level and greater tibial plateau
bone area, independent of body size (height) and BMI. Since both
BMLs and tibial bone area expansion represent early structural
changes that antedate the articular cartilage changes and the
development of knee OA28,29, our ﬁndings suggest that uCTX-II may
be a sensitive biomarker of early subchondral bone changes asso-
ciated with the development of knee OA.P value Multivariate analysisz P value
Regression coefﬁcient/OR (95% CI)
0.01 80.2 (9.3, 151.1) 0.03
0.004 86.0 (33.3, 138.7) 0.002
0.26 2.97 (0.49, 18.11) 0.24
0.01 10.62 (1.82, 61.85) 0.01
Table V
Association between uCTX-II and subchondral bone changes over 2 years
Univariate analysis P value Multivariate analysisz P value
Regression coefﬁcient/OR (95% CI) Regression coefﬁcient/OR (95% CI)
Annual change in tibial bone area (%)*
Medial tibial bone area 0.18 (0.85, 0.49) 0.60 0.09 (0.69, 0.87) 0.82
Lateral tibial bone area 0.25 (1.52, 1.01) 0.69 0.68 (2.16, 0.80) 0.37
Deterioration of BMLs (yes/no)y
Medial tibiofemoral BMLs 6.03 (1.36, 26.68) 0.02 5.12 (0.92, 28.65) 0.06
Lateral tibiofemoral BMLs 0.92 (0.12, 7.60) 0.94 0.69 (0.06, 7.66) 0.77
* Regression coefﬁcient.
y OR.
z Adjusted for age and BMI.
Table IV
Association between uCTX-II and knee cartilage changes over 2 years
Univariate analysis P value Multivariate analysisz P value
Regression coefﬁcient/OR (95% CI) Regression coefﬁcient/OR (95% CI)
Annual change in tibial cartilage volume (%)*
Medial tibial cartilage volume 0.13 (0.96, 1.23) 0.81 0.13 (1.19, 1.44) 0.85
Lateral tibial cartilage volume 0.94 (1.92, 0.04) 0.06 0.74 (1.94, 0.46) 0.22
Deterioration of cartilage defects (yes/no)y
Medial tibiofemoral cartilage defects 1.24 (0.58, 2.65) 0.58 1.36 (0.54, 3.40) 0.51
Lateral tibiofemoral cartilage defects 1.43 (0.69, 2.97) 0.34 1.95 (0.78, 4.85) 0.15
* Regression coefﬁcient.
y OR.
z Adjusted for age, BMI, and baseline tibial bone area.
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not have knee radiographs, so we cannot exclude women with
asymptomatic early radiological knee OA. This study examined
community-based women without clinical knee disease who thus
have low rates of cartilage volume loss, tibial plateau bone
expansion, and deterioration of cartilage defects and BMLs. Thus
this study may not have enough power to show the predictive ef-
fect of uCTX-II on knee structural changes over the time of this
study, which was only 2 years. Studies with larger sample size and
prolonged follow-up period are needed to examine the longitudinal
associations in a pre-clinical population. The results may not be
generalizable to those with symptomatic knee OA since the rate of
cartilage and bone changes is higher in this population16,17. There is
evidence for a diurnal variation of uCTX-II and uCTX-II concentra-
tion varies with morning activity30. It may be that one single
measurement of uCTX-II is not the best predictor for longitudinal
structural changes and measurements at multiple time points may
be needed. However these limitations are likely to have reduced
our ability to show a signiﬁcant association. Furthermore, uCTX-II is
a systemic biomarker. Previous studies have shown increased
uCTX-II levels in patients with spinal cord injury31 and rapidly
destructive hip OA32, suggesting that uCTX-II is not a speciﬁc
biomarker for the knee joint and may be a product of the meta-
bolism of cartilage and bone from elsewhere. Despite this, uCTX-II
was associated with early structural changes at the knee. The
strength of this study is that we were able to detect a signiﬁcant
relationship between uCTX-II and early structural changes in
healthy knees prior to the onset of clinical knee disease. This is a
potentially important population to target for the prevention and
early treatment of knee OA.
This study provides a new insight into the relationship between
higher uCTX-II levels and adverse early knee structural features
that are associated with OA in middle-aged womenwithout clinical
knee disease. The ﬁndings suggest that uCTX-II may be a sensitive
biomarker of early cartilage and subchondral bone changes in knee
OA. Although further work will be needed to determine itssensitivity to change and whether it predicts progression of disease
over longer time periods, uCTX-II may be used as a biomarker to
identify people with early knee structural changes who might be
the target for early OA intervention.Author contributions
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